Dr. John Cush RheumNow
1 year 11 months ago
Metanalysis of 40 papers, 486,465 RA pts & 3,928 incident ILD outcomes shows no signif risk of ILD w/ DMARD use; no ILD risk w/ TOFA or TNFi (Oral Surveillance n=2,911; OR 0.94). MTX use yielded a Lower ILD risk (OR 0.49; 0.32 to 0.76) vs no MTX use. https://t.co/Es8yyEiD8r https://t.co/qOYPkWNi9o
Dr. John Cush RheumNow
1 year 11 months ago
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
Dr. John Cush RheumNow
1 year 11 months ago
#SLE and biologics (approved & under study) - Full read review:
Anifrolumab
Belimumab
Ocrelizumab
Obinutuzumab
Ofatumumab
Veltuzumab
Epratuzumab
Tocilizumab
Secukinumab
Ustekinumab
Eculizumab https://t.co/EwplhAPYJH https://t.co/7Vgn2Rtd4f
Dr. John Cush RheumNow
1 year 11 months ago
Early bird registration for RheumNow Live is now open! Join us Feb 8-9 in Dallas, TX.
Join the Revolution in Rheumatology Education!
https://t.co/ygjZRMVkOZ
Dr. John Cush RheumNow
1 year 11 months ago
Men and Women Process Pain Differently
Men and women experience pain relief differently; a new study may help explain why women have more chronic pain and are less responsive to opioid treatments.
https://t.co/MYWAZnqGmA https://t.co/TxofSlsI4M
Dr. John Cush RheumNow
1 year 11 months ago
Health Disparities in DMARD Use in RA
A UK study shows biological and targeted synthetic DMARD (b/tsDMARDs) use in newly diagnosed rheumatoid arthritis (RA) varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply.
https://t.co/t7O99FM7fQ https://t.co/CtvfblpPUo
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dr. John Cush RheumNow
1 year 11 months ago
Cardiovascular health (CVH) is critical in arthritis care. NHANES study 5919 arthritis pts finds 10-point incr, in CVH score yielded significantly lower all-cause mortality risk (adj HR 0.72; 0.67–0.79); best results with OA/DJD, more than inflammatory arthritis.… https://t.co/etBbH7bH1D https://t.co/1is2VlT5sl
Dr. John Cush RheumNow
1 year 11 months ago
ACR and Congress Address “Damaging” Cuts to Medicare MD Payments
The ACR commended the 233 bipartisan representatives who signed a letter urging House Speaker Mike Johnson (R-LA) and Minority Leader Hakeem Jeffries (D-NY) to support legislative action to address “damaging”… https://t.co/nVhRAeBf7y https://t.co/GwQTAi7GR1
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.
A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life. Patients with rheumatoid arthritis pay an average of $3,383 more per year on health care expenditures than those without the disorder, according to the study published in ACR Open Rheumatology, the American College of
Dr. John Cush RheumNow
1 year 11 months ago
Eu Heart J - Cardiometabolic risk factors in RA Pregancy rose in last 15 yrs. RA-Preg at higher risk of preeclampsia, peripartum cardiomyopathy, arrhythmias, acute kidney injury, venous thromboembolism during hospitalizations. https://t.co/7SnjWFluCf https://t.co/H93ELPZWWz
Men and women experience pain relief differently; a new study may help explain why women have more chronic pain and are less responsive to opioid treatments.
A UK study shows biological and targeted synthetic DMARD use in newly diagnosed rheumatoid arthritis varies markedly by ethnicity, age and setting - "one-size-fits-all approach" does not apply.
